Loading...
Market
How will J&J's stock react to Intra-Cellular acquisition by March 31, 2025?
3
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 0-10% • 25%
No change • 25%
Decrease • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6B at JPM25
Jan 13, 2025, 03:04 PM
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies, a developer of treatments for central nervous system disorders, for approximately $14.6 billion. The deal, announced at the J.P. Morgan Healthcare Conference (JPM25) in San Francisco, marks the largest public biotech acquisition in over a year. Intra-Cellular Therapies' schizophrenia drug, Caplyta, is among the assets J&J will gain through this acquisition. The transaction is set to be completed within the year, with J&J offering $132 per share, a 39% premium over Intra-Cellular's closing stock price on the previous Friday. This move is seen as a strategic fit for J&J, aiming to bolster its growth in the neurosciences sector.
View original story
Similar markets
Increase by more than 10% • 25%
Decrease • 25%
No significant change • 25%
Increase by 5-10% • 25%
No official outcome by end of 2025 • 25%
Acquisition completed • 25%
Acquisition delayed • 25%
Acquisition abandoned • 25%
Acquisition Completed • 25%
Other Outcomes • 25%
Acquisition Delayed • 25%
Acquisition Abandoned • 25%
J&J stock remains within 5% of current price • 25%
J&J stock falls by more than 5% • 25%
J&J stock rises by more than 5% • 25%
Other • 25%
Increase by more than 10% • 25%
No significant increase • 25%
Increase by less than 5% • 25%
Increase by 5-10% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%